Skip to content

Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients

Hypothalamic fMRI Response to Nutrients

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00686608
Enrollment
56
Registered
2008-05-30
Start date
2006-10-01
Completion date
2015-07-01
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity

Brief summary

The purpose of this study is to identify how certain parts of the brain that control appetite respond to changes in dietary carbohydrate and fat.

Detailed description

To measure fMRI signal change in hypothalamic and brainstem centers associated with control of food intake and energy expenditure in response to IV glucose, fructose, and saline. The fMRI response to these nutrients will then be compared in obese vs. lean subjects. Frequently timed blood samples will be obtained for measurement of nutrients (i.e., glucose) and blood levels of other factors (i.e., insulin, ghrelin, lactate) during these infusion protocols, and to test associations between these levels and the fMRI response.

Interventions

DIETARY_SUPPLEMENTglucose

0.3mg/kg of glucose

DIETARY_SUPPLEMENTfructose

fructose IV bolus

DIETARY_SUPPLEMENTsaline

IV saline

Sponsors

Oregon Health and Science University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Participants will receive infusions of glucose, fructose, and saline in a randomized order.

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18 year to 45 years of age * BMI 18 to 25 kg/m2 (25 subjects) and 30 to 40 kg/m2 (25 subjects), matched for age and sex. * At maximal lifetime weight. * Weight stable for at least 3 months.

Exclusion criteria

* Those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes. * Subjects taking psychiatric or centrally-acting (CNS) medications, or who are diagnosed with a psychiatric or neurological illness, including: depression, anorexia, bulimia, and seizure disorder. * Subjects who have lost weight as a result of dieting, pharmacological treatment, or bariatric surgery. * Weight \> 350 lbs or girth \> 60 inches (the limits of the MR machine) * Exercise \> 30 minutes, 3 times a week. * Alcohol consumption \> 2 drinks / day. * Weight \> 300 lbs (150 kg) (weight limit for MR machine). * Blood glucose \> 100 mg/dL, abnormal creatinine or liver function tests. * Illicit drug use. * Pregnancy. * Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary carbohydrate, protein, or fat intakes. * Those with a contraindication to exposure to strong magnetic fields: presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips. * Those with claustrophobia.

Design outcomes

Primary

MeasureTime frame
The primary outcomes of this aim will be the change in fMRI response in the hypothalamus to IV glucose, to IV glucose during intralipid infusion, and to the IV glucose alone, in the lean and obese groups separately.0,1,2 and 3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026